Fig. 8

MrgD interacted with p-P38 in the nuclei. A, The increase of p-P38 MAPK and PKA induced by Ang II were inhibited by MrgD downregulation in NRCM. B, The increase of p-P38 MAPK induced by Ang II was inhibited by MrgD downregulation in NRCF. C-D, SB203580 pre-treatment ameliorated Ang II-induced NRCM hypertrophy NRCF fibrosis. E, MrgD shRNA inhibited Ang II-induced nuclear import of p-P38 in NRCF, which could be reversed by PTX pretreatment. F, Ad-MrgD has no extra effects on enhancing Ang II-induced nuclear import of p-P38 in NRCF. G, immunofluorescence staining of NRCF with antibodies against α-SMA and p-P38 (α-SMA, green; p-P38, red; DAPI, blue; scale bar: 50 μM). H, Co-IP experiments verified that MrgD interacted with p-P38 in the nuclei. The data are expressed as mean ± SEM. n = 3, 4 or 5 biological replicates per group. ^nsP > 0.05, ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, ^****P < 0.0001